Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Jan 4, 2019
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Sale
Common Stock
2019-01-03$19.48/sh−375$7,305→ 4,000 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.